Key facts
- It has raised $270K; the latest was Later Stage VC ($270K) in Dec 2025.
- Notable investors include SFC Capital, Cambridge Enterprise Ventures, Cancer Research Horizons, Start Codon.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Verinnogen
- ·The full record, as it builds
Funding rounds
No funding rounds for Verinnogen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Verinnogen
Developer of a hand-held device designed to profile three-dimensional surfaces for pre-clinical cancer research. The company offers tools that improve accuracy and reduce operator error, enabling researchers to achieve more efficient translation of cancer therapies for clinical evaluation.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2019
- Employees
- 6
- Website
- verinnogen.com/
- Ownership
- Privately Held (backing)
Verinnogen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verinnogen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verinnogen in its N-PORT filings yet. We sweep new filings monthly.